Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$833 Mln
P/E Ratio
--
P/B Ratio
2.05
Industry P/E
--
Debt to Equity
0.1
ROE
-0.05 %
ROCE
-0 %
Div. Yield
0 %
Book Value
8.07
EPS
-0
CFO
$147.57 Mln
EBITDA
$140.50 Mln
Net Profit
$84.26 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
STAAR Surgical (STAA)
| -29.31 | -3.10 | -25.38 | -62.99 | -36.05 | -14.27 | 6.66 |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
STAAR Surgical (STAA)
| -22.01 | -35.70 | -46.83 | 15.25 | 125.25 | 10.22 | 105.06 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.28 | 10,289.47 | 14.38 | 12.69 | |
| 70.06 | 9,544.04 | 92.52 | 2.52 | |
| 152.07 | 8,064.21 | -- | -25.23 | |
| 277.22 | 10,728.90 | 773.26 | 1.2 |
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens... product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. Address: 25510 Commercentre Drive, Lake Forest, CA, United States, 92630 Read more
President, CEO & Chairman
Mr. Thomas G. Frinzi
President, CEO & Chairman
Mr. Thomas G. Frinzi
Headquarters
Lake Forest, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of STAAR Surgical Company (STAA) stood at $ 510 Mln as on 31-Dec-24
The share price of STAAR Surgical Company (STAA) is $17.17 (NASDAQ) as of 22-Apr-2025 16:00 EDT. STAAR Surgical Company (STAA) has given a return of -36.05% in the last 3 years.
STAAR Surgical Company (STAA) has a market capitalisation of $ 833 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of STAAR Surgical Company (STAA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the STAAR Surgical Company (STAA) and enter the required number of quantities and click on buy to purchase the shares of STAAR Surgical Company (STAA).
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. Address: 25510 Commercentre Drive, Lake Forest, CA, United States, 92630
The CEO & director of Mr. Thomas G. Frinzi. is STAAR Surgical Company (STAA), and CFO & Sr. VP is Mr. Thomas G. Frinzi.
There is no promoter pledging in STAAR Surgical Company (STAA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| STAAR Surgical Company (STAA) | Ratios |
|---|---|
|
Return on equity(%)
|
-0.01
|
|
Operating margin(%)
|
-4.02
|
|
Net Margin(%)
|
-0.01
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of STAAR Surgical Company (STAA) was No Profit.
$0.64
(
